Filing Flows › Sonoma Pharmaceuticals (SNOA) › Q4 FY25
Sonoma Pharmaceuticals (SNOA) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Jun 17, 2025
Sonoma Pharmaceuticals (SNOA) reported revenue of $3.8M for the fourth quarter fiscal 2025 (Q4 FY25), +9% from a year earlier and +5% from the quarter before. Operating margin was -17.5%, net loss $776K (20.7% of revenue).
Sonoma Pharmaceuticals, Q4 FY25: revenue $3.8M (+9% year over year), operating margin -17.5%, net loss $776K, operating cash flow −$95K. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.8M | +5% | +9% |
| Operating profit | −$656K | — | — |
| Net earnings | −$776K | — | — |
| Operating cash flow | −$95K | -117% | — |
What changed
Revenue was $3.8M in Q4 FY25, up 9% year over year and up 5% from the previous quarter.
Gross margin was 40.7%, up 9.0 points from a year earlier. Operating costs exceeded revenue by $656K, an operating margin of -17.5%. Operating expenses fell 13% while revenue rose 9%. The quarter ended with a net loss of $776K, narrower than the previous quarter's $928K loss. Non-operating items added $128K, -24% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$95K. Non-cash charges added back $31K of depreciation and amortization and $90K of share-based compensation. Working capital and other items added $560K. Capital expenditures of $47K exceeded it, leaving free cash flow of −$142K.
Questions
What was Sonoma Pharmaceuticals' revenue in the fourth quarter fiscal 2025?
Sonoma Pharmaceuticals (SNOA) reported revenue of $3.8M for the fourth quarter fiscal 2025 (Q4 FY25), +9% from a year earlier and +5% from the quarter before.
Was Sonoma Pharmaceuticals profitable in the fourth quarter fiscal 2025?
Operating loss was $656K (-17.5% of revenue) and net loss $776K.